Back to Search

Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

  • Protocol Number: 202111094
  • Principal Investigator: Peterson, Lindsay
  • Cancer Types: Breast

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions